Liquid nitrogen spray cryotherapy in Barrett's esophagus with high-grade dysplasia: long-term results

Abstract

Background: Liquid nitrogen endoscopic spray cryotherapy can safely and effectively eradicate high-grade dysplasia in Barrett's esophagus (BE-HGD). Long-term data on treatment success and safety are lacking.

Objective: To assess the long-term safety and efficacy of spray cryotherapy in patients with BE-HGD.

Design: Single-center, retrospective study.

Setting: Tertiary-care referral center.

Patients: A total of 32 patients with BE-HGD of any length.

Intervention: Patients were treated with liquid nitrogen spray cryotherapy every 8 weeks until complete eradication of HGD (CE-HGD) and intestinal metaplasia (CE-IM) was found by endoscopic biopsy. Surveillance endoscopy with biopsies was performed for at least 2 years.

Main outcome measurements: CE-HGD, CE-IM, durability of response, disease progression, and adverse events.

Results: CE-HGD was 100% (32/32), and CE-IM was 84% (27/32) at 2-year follow-up. At last follow-up (range 24-57 months), CE-HGD was 31/32 (97%), and CE-IM was 26/32 (81%). Recurrent HGD was found in 6 (18%), with CE-HGD in 5 after repeat treatment. One patient progressed to adenocarcinoma, downgraded to HGD after repeat cryotherapy. BE segment length ≥3 cm was associated with a higher recurrence of IM (P = .004; odds ratio 22.6) but not HGD. No serious adverse events occurred. Stricture was seen in 3 patients (9%), all successfully dilated.

Limitations: Retrospective study design, small sample size.

Conclusion: In patients with BE-HGD, liquid nitrogen spray cryotherapy has an acceptable safety profile and success rate for eliminating HGD and IM and is associated with a low rate of recurrence or progression to cancer with long-term follow-up.

Keywords: BE; BE with high-grade dysplasia; BE-HGD; Barrett's esophagus; CE-HGD; CE-IM; HGD; IM; PPI; RFA; complete eradication of high-grade dysplasia; complete eradication of intestinal metaplasia; high-grade dysplasia; intestinal metaplasia; proton pump inhibitor; radiofrequency ablation.